logo
Bio-reclamation tech turns rocky belt of Koraon into green areas

Bio-reclamation tech turns rocky belt of Koraon into green areas

Time of India23-04-2025

1
2
3
Prayagraj:
Bio-reclamation technology
seems to have worked in the rocky and barren lands of the trans-Yamuna pocket of the Prayagraj district, as farmers are now able to plant trees and grasses of special species. Microbes have also been released into the soil, which are changing its structure.
With both union and state govt's taking several steps to make barren and wasteland fertile, the state govt is a step ahead in offering assistance to small and marginal farmers through the
Deendayal Upadhyay Kisan Samridhi Yojana
. This initiative aims to improve their infertile or less fertile land. On the other hand, it is making the soil fertile and productive through various
agro-forestry projects
.
Experts claimed that the bio-reclamation technology is proving to be effective in the rocky and barren region of the Koraon belt of Sangam City. Bio-reclamation techniques refer to measures that use living organisms, primarily microorganisms, to restore or rehabilitate degraded land or remove pollutants from contaminated environments. This technique involves processes like
microbial leaching
, where microbes break down substances or extract metals from materials, or using plants to degrade pollutants from soil and water.
The Forest Research Centre for Eco-Rehabilitation Department is making barren and wasteland cultivable by using bio-reclamation techniques. Dr Kumud Dubey, a scientist at the Ecological Restoration Centeer in Prayagraj, says, "A project was launched in the Koraon area of the Prayagraj district at a cost of Rs 38 lakhs, which has now started showing positive results. For this, trees and grasses of special species wereplanted here. Similarly, microbes have also been released into the soil, which are changing its structure."
A large area of Koraon is completely rocky and barren. It neither has microbes that create fertility nor trees that can absorb moisture and provide a solution to the problem of falling water levels in the area. The bio-reclamation technology has been used in three selected clusters in the area.
Dr Dubey said, "In each cluster, 500 to 600 species of trees have been planted, which retain moisture and are effective in maintaining the water level." This quality is found in the species of Milia, Acacia Senegal, and Mahua, which have been planted. Apart from this, Dinanath grass and lemon grass, which grow in very little water, have also been planted here to prevent soil erosion. Similarly, many types of microbes have also been sprayed here to make the soil fertile. This includes nitrogen-fixing microbes, phosphorus, and zinc-storing microbes. With these efforts, the rocky land of the area has become green and the quality of the soil has changed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Govt clears Rs 215cr lifescience project in Thonnakkal
Govt clears Rs 215cr lifescience project in Thonnakkal

Time of India

time20 hours ago

  • Time of India

Govt clears Rs 215cr lifescience project in Thonnakkal

Thiruvananthapuram: The state govt has approved a Rs 215-crore investment proposal by the Council of Scientific and Industrial Research – National Institute for Interdisciplinary Science and Technology (CSIR-NIIST) at the Bio360 Life Science Park in Thonnakkal, Thiruvananthapuram. An order issued by the industries department on June 7 also permits the allotment of 10 acres of land to CSIR-NIIST on a lease of up to 90 years at no financial cost. The allotted land falls within the area designated for the second phase of development at the Bio360 Life Science Park, developed by Kerala Lifescience Industries Park Pvt Ltd (KLIP), a state-incorporated company promoting lifescience industries. The approval follows a proposal submitted in Sept 2024 by the KLIP managing director to establish a CSIR-NIIST Centre for Innovation, Technology, and Entrepreneurship. The initiative includes a pilot plant for solar-aided hydrogen production from wastewater, supported by the department of science and technology and the state govt. It also proposes a bio-manufacturing hub under a Rs 115-crore joint submission by CSIR-NIIST and KLIP to the Biotechnology Industry Research Assistance Council (Birac). Additional components include a production facility for bio-polymers and bio-based alternatives to plastic and animal leather, funded by CSIR and private industry partners. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Plans also involve creating a manufacturing and standardisation hub for Ayush products in collaboration with the ministry of Ayush and industrial stakeholders. A regional resource development centre focused on rubber, coir and spices is also proposed, to be implemented under public-private partnership models and supported by govt schemes. The land allotment falls under the unified industrial land and building allotment and disposal regulations introduced in 2024 for Kinfra and KSIDC. These rules allow leasing a minimum of 10 acres for projects with investments above Rs 100 crore, for up to 90 years, subject to conditions. The investor must bring in Rs 100 crore within three years, with employment generation in line with the investment scale. All allotments require approval from the State Industrial Land Allotment Committee. If the investment exceeds Rs 300 crore, additional incentives may be granted by a high-power committee led by the chief secretary, as per the state's industrial policy. This marks one of the largest projects in the park's second phase, with timelines and employment targets set to guide its progress.

IIT Madras BS degree convocation marks milestone in democratizing tech education
IIT Madras BS degree convocation marks milestone in democratizing tech education

Time of India

timea day ago

  • Time of India

IIT Madras BS degree convocation marks milestone in democratizing tech education

MUMBAI: On a day marked by quiet revolutions and roaring applause, the Indian Institute of Technology Madras held its Convocation and Certificate Distribution Ceremony for the BS Degree programmes on 8 June 2025—a moment that didn't just honour graduates but redefined who gets to be called one. In an auditorium humming with possibility, 867 students from across India and abroad received their scrolls—some holding three-year BSc degrees, others the first-ever batch to earn the four-year BS degrees in Data Science and Applications or in Electronic Systems. Among them were students from remote villages, urban sprawls, and even foreign cities. Some were just 18, others over 80. 'This is not just a graduation. It's a declaration,' said Prof. V. Kamakoti, Director, IIT Madras. 'That knowledge belongs to all. That no income bracket or geography or prior degree should keep someone from accessing world-class education.' Of the graduating cohort, nearly 150 come from families earning less than Rs 1 lakh annually. Another 100 come from households earning less than Rs 5 lakh. These degrees were not easy. Delivered online but assessed rigorously in person at exam centres across India and abroad, they are as academically demanding as any other degree from IIT Madras. They come with projects, labs, capstones—and grit. More than half the students (52%) are juggling this programme alongside another undergraduate degree. While 72% come from engineering or technical fields, a significant 22% come from arts, commerce, or sciences—each drawn by the programme's promise to rewire careers and reimagine futures. Among those honoured was Dr. Sadineni Nikhil Chowdary, an MBBS doctor from AIIMS Delhi, who not only graduated with a CGPA of 9.82 but also topped the GATE Data Science and AI exam. He now plans to pursue MTech at IIT Madras, showing that medicine and machine learning are not parallel tracks but converging ones. 'Three of the top 10 ranks in GATE DA were secured by our BS students,' noted Prof. Kamakoti. 'That speaks volumes of the academic depth this programme fosters.' The day also underscored a larger vision. With over 38,000 active learners and growing, this hybrid BS programme is IIT Madras' blueprint for Sustainable Development Goal 4: universal access to quality education. Whether it's a diploma, a BSc, or a full BS degree, students have flexible exits—and for some, even free rides, thanks to CSR support. 'We're not just building coders or data scientists,' said Prof. Andrew Thangaraj, Coordinator of the BS Program. 'We're shaping informed problem-solvers who understand both complexity and context—who can write code, but also ask the right questions.' Chief Guest Mr. Aravind Krishnan, Managing Director and Head, Southeast Asia Private Equity, Blackstone, described the programme as 'a global model for accessible, future-ready education,' adding that 'the ability to extract insights from complexity is now among the most valuable skills of our time.' Today, more than 4,800 students are studying tuition-free thanks to philanthropic support. Over 10,000 students from extremely low-income families receive up to 75% scholarship. Some have already secured admission into institutions like IISc, IITB, IITD, ISB, University of Michigan, and Texas A&M. What started as a bold experiment is now a quiet revolution. In a world obsessed with exclusivity, IIT Madras is building a new kind of legacy—one where excellence is not rarefied, but reachable.

Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane
Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane

Business Standard

timea day ago

  • Business Standard

Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane

Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets. Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSources integrated drug substance and drug product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbranes global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbranes latest funding round, reinforcing the long-term alignment between the two companies. Neeraj Sharma, managing director & CEO of OneSource Specialty Pharma, said: The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbranes proven success in biosimilar development, combined with OneSources fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the worlds leading biotech companies. OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store